Outcome of percutaneous HeartMate3 decommissioning: A single-centre experience

Hassane Abdallah; Elena Grasso; M Ibrahem Abdelhamed; Ahmed Ibrahim; Metin Segur; Khalid Al Khamees; Roberto Lorusso

doi:10.1111/aor.14279

Outcome of percutaneous HeartMate3 decommissioning: A single-centre experience

Hassane Abdallah^*
, Elena Grasso
, M Ibrahem Abdelhamed
, Ahmed Ibrahim
, Metin Segur
, Khalid Al Khamees
, Roberto Lorusso

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVES: To highlight the role of percutaneous left ventricular assist device (LVAD) decommissioning as a safe procedure after myocardial recovery in patients with advanced heart failure.

BACKGROUND: The HeartMate3 LVAD (Abbott, Chicago, IL, USA) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. Most VADs are used as a bridge to heart transplantation; however, in certain cases, myocardial function recovers, and VADs can be explanted after the patient is weaned. Although surgical explantation remains the gold standard, minimally invasive percutaneous decommissioning has been described as a successful alternative. In this study, we present our experience, one-year outcomes, and adverse events associated with percutaneous LVAD decommissioning.

METHODS: We conducted a retrospective review of data from six consecutive patients who underwent percutaneous LVAD decommissioning.

RESULTS: Six patients were enrolled in the study. For all six patients, HM3 decommissioning was completed at least 6 months ago. No technical complications were documented. No strokes were observed within the study period, and the ejection fraction improved. The mean follow-up duration was 18 ± 8.5 months, and the survival rate was 100%.

CONCLUSION: Percutaneous HeartMate3 decommissioning appears to be safe. In particular, the survival after the procedure was 100%, and no events, especially thromboembolic ones, occurred.

Original language	English
Pages (from-to)	1429-1435
Number of pages	7
Journal	Artificial Organs
Volume	46
Issue number	7
Early online date	12 May 2022
DOIs	https://doi.org/10.1111/aor.14279
Publication status	Published - Jul 2022

Keywords

EXPLANTATION
IMPLANTATION
MYOCARDIAL RECOVERY
PUMP
VENTRICULAR ASSIST DEVICE
decommissioning
left ventricular assist device
percutaneous
recovery

Access to Document

10.1111/aor.14279

Cite this

@article{bec9128c61de45e89427e663c94a7f3b,

title = "Outcome of percutaneous HeartMate3 decommissioning: A single-centre experience",

abstract = "OBJECTIVES: To highlight the role of percutaneous left ventricular assist device (LVAD) decommissioning as a safe procedure after myocardial recovery in patients with advanced heart failure.BACKGROUND: The HeartMate3 LVAD (Abbott, Chicago, IL, USA) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. Most VADs are used as a bridge to heart transplantation; however, in certain cases, myocardial function recovers, and VADs can be explanted after the patient is weaned. Although surgical explantation remains the gold standard, minimally invasive percutaneous decommissioning has been described as a successful alternative. In this study, we present our experience, one-year outcomes, and adverse events associated with percutaneous LVAD decommissioning.METHODS: We conducted a retrospective review of data from six consecutive patients who underwent percutaneous LVAD decommissioning.RESULTS: Six patients were enrolled in the study. For all six patients, HM3 decommissioning was completed at least 6 months ago. No technical complications were documented. No strokes were observed within the study period, and the ejection fraction improved. The mean follow-up duration was 18 ± 8.5 months, and the survival rate was 100\%.CONCLUSION: Percutaneous HeartMate3 decommissioning appears to be safe. In particular, the survival after the procedure was 100\%, and no events, especially thromboembolic ones, occurred.",

keywords = "EXPLANTATION, IMPLANTATION, MYOCARDIAL RECOVERY, PUMP, VENTRICULAR ASSIST DEVICE, decommissioning, left ventricular assist device, percutaneous, recovery",

author = "Hassane Abdallah and Elena Grasso and Abdelhamed, \{M Ibrahem\} and Ahmed Ibrahim and Metin Segur and \{Al Khamees\}, Khalid and Roberto Lorusso",

note = "{\textcopyright} 2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.",

year = "2022",

month = jul,

doi = "10.1111/aor.14279",

language = "English",

volume = "46",

pages = "1429--1435",

journal = "Artificial Organs",

issn = "0160-564X",

publisher = "John Wiley \& Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Outcome of percutaneous HeartMate3 decommissioning

T2 - A single-centre experience

AU - Abdallah, Hassane

AU - Grasso, Elena

AU - Abdelhamed, M Ibrahem

AU - Ibrahim, Ahmed

AU - Segur, Metin

AU - Al Khamees, Khalid

AU - Lorusso, Roberto

PY - 2022/7

Y1 - 2022/7

N2 - OBJECTIVES: To highlight the role of percutaneous left ventricular assist device (LVAD) decommissioning as a safe procedure after myocardial recovery in patients with advanced heart failure.BACKGROUND: The HeartMate3 LVAD (Abbott, Chicago, IL, USA) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. Most VADs are used as a bridge to heart transplantation; however, in certain cases, myocardial function recovers, and VADs can be explanted after the patient is weaned. Although surgical explantation remains the gold standard, minimally invasive percutaneous decommissioning has been described as a successful alternative. In this study, we present our experience, one-year outcomes, and adverse events associated with percutaneous LVAD decommissioning.METHODS: We conducted a retrospective review of data from six consecutive patients who underwent percutaneous LVAD decommissioning.RESULTS: Six patients were enrolled in the study. For all six patients, HM3 decommissioning was completed at least 6 months ago. No technical complications were documented. No strokes were observed within the study period, and the ejection fraction improved. The mean follow-up duration was 18 ± 8.5 months, and the survival rate was 100%.CONCLUSION: Percutaneous HeartMate3 decommissioning appears to be safe. In particular, the survival after the procedure was 100%, and no events, especially thromboembolic ones, occurred.

AB - OBJECTIVES: To highlight the role of percutaneous left ventricular assist device (LVAD) decommissioning as a safe procedure after myocardial recovery in patients with advanced heart failure.BACKGROUND: The HeartMate3 LVAD (Abbott, Chicago, IL, USA) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. Most VADs are used as a bridge to heart transplantation; however, in certain cases, myocardial function recovers, and VADs can be explanted after the patient is weaned. Although surgical explantation remains the gold standard, minimally invasive percutaneous decommissioning has been described as a successful alternative. In this study, we present our experience, one-year outcomes, and adverse events associated with percutaneous LVAD decommissioning.METHODS: We conducted a retrospective review of data from six consecutive patients who underwent percutaneous LVAD decommissioning.RESULTS: Six patients were enrolled in the study. For all six patients, HM3 decommissioning was completed at least 6 months ago. No technical complications were documented. No strokes were observed within the study period, and the ejection fraction improved. The mean follow-up duration was 18 ± 8.5 months, and the survival rate was 100%.CONCLUSION: Percutaneous HeartMate3 decommissioning appears to be safe. In particular, the survival after the procedure was 100%, and no events, especially thromboembolic ones, occurred.

KW - EXPLANTATION

KW - IMPLANTATION

KW - MYOCARDIAL RECOVERY

KW - PUMP

KW - VENTRICULAR ASSIST DEVICE

KW - decommissioning

KW - left ventricular assist device

KW - percutaneous

KW - recovery

U2 - 10.1111/aor.14279

DO - 10.1111/aor.14279

M3 - Article

C2 - 35554959

SN - 0160-564X

VL - 46

SP - 1429

EP - 1435

JO - Artificial Organs

JF - Artificial Organs

IS - 7

ER -

Outcome of percutaneous HeartMate3 decommissioning: A single-centre experience

Abstract

Keywords

Access to Document

Fingerprint

Cite this